drug
aficamten
Marketedupdated 5mo agoby $CYTK CYTOKINETICS INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Preapproval (across all indications), with 2 investigational indications.
all catalysts(2)
Trials studying aficamten
- phase3A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- phase3A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
- phase3Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
- phase3Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
- phase3Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
- phase3An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
- phase1Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 19, 2030
~4.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Jul 15, 2042method-of-use (U-4371)US 12370179
- Jul 15, 2042method-of-use (U-4371)US 12370179
- Jul 15, 2042method-of-use (U-4371)US 12370179
- Jul 15, 2042method-of-use (U-4371)US 12370179
- Jan 18, 2039compositionUS 10836755
- Jan 18, 2039compositionUS 10836755
- Jan 18, 2039compositionUS 10836755
- Jan 18, 2039compositionUS 10836755
FDA exclusivities (4)
- Dec 19, 2030NCENew Chemical Entity (5y)4.2y
- Dec 19, 2030NCENew Chemical Entity (5y)4.2y
- Dec 19, 2030NCENew Chemical Entity (5y)4.2y
- Dec 19, 2030NCENew Chemical Entity (5y)4.2y
News(10)
- ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsyAt a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.biopharma_dive · 29d ago
- A winner, a loser, and a mid-stage signal from a major cardiology research conferenceThe mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from Morning Roundsstat · 29d ago
- STAT+: Cytokinetics details trial win for what could be its next approvalIt took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second could come much faster.stat · 1mo ago
- #ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approvalMUNICH — Cytokinetics’ heart drug Myqorzo could gain expanded approval next year, potentially doubling its market reach, after detailed results backed the drug’s use in a heart muscle disease. The…endpoints · 1mo ago
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 1mo ago
- Braveheart pumps more life into biotech IPO market with $382M expected debutBraveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.biospace · 1mo ago
- Braveheart charges past expectations with $382.5M IPO to fund cardio drug from HengruiBraveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.fiercebiotech · 1mo ago
- Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.fiercebiotech · 2mo ago
- Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunoBraveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is lookin…biospace · 2mo ago
- Braveheart, Attovia join next wave of biotech IPOsThe two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.biopharma_dive · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that